NL-OMON20806已完成不适用
A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML.
Erasmus MC, Rotterdam, The Netherlands0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Established diagnosis of relapsed MDS or JMML according to EWOG-criteria, after a prior stem cell transplantation;
- •2. 1 month to ≤ 18 years old;
排除标准
- •1. Prior or current history:
- •o Other serious illnesses or medical conditions
研究者
相似试验
进行中（未招募）
1 期
Azacitidine in children with MDS or JMMEUCTR2010-022235-10-DEErasmus MC65
进行中（未招募）
不适用
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 15.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2010-022235-10-ITErasmus MC65
进行中（未招募）
1 期
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 17.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2010-022235-10-ESErasmus MC5
进行中（未招募）
1 期
Azacitidine in children with MDS or JMMEUCTR2010-022235-10-DKErasmus MC65
招募中
2 期
A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMMMDS and JMML10018865NL-OMON47695Erasmus MC, Universitair Medisch Centrum Rotterdam3